Vascular Biogenics Ltd (VBLT)

[Oren1976]

I think you brought these numbers from clinical success rate 2006-2015 pdf in google search but if u look deeper into the numbers although u are right that the average success rate in oncology in phase 2 is 24.6% this is average and not applicable to the cancers vblt deal with. If u look at phase 3 success the average is 40% but pancreatic has 13% success and ovarian is under 30%. I took these 2 phase 3 and went to phase 2 assuming same relative numbers my numbers of less than 10% make sense. Ovarian on his own is less than 20% in ph2 usong relative numbers but we dont deal with ovarian we deal with platinum resistant ovarian and in this subgroup vblt had great success in refractory platinum resistant which take us to less than 10% success rate. Gbm is lets say same as pancreatic the hardest of the hard which takes us to less than 10% but we dont deal with gbm we deal with recurrent gbm which is worse so less than 10% chance is being conservative. Then we have thyroid but it is not really thyroid its a very rare aggressive type thyroid that overcome all treatments including most advanced again less than 10% chance...